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Background: The goal of this article is to present clinical and patency results of endovascular treatment of nonmalignant,
iliocaval venous obstructive disease and to discuss the evolution of technical details.
Methods: From November 1995 to June 2004, 44 patients (female-male ratio, 3.9:1; left-right lower limb ratio, 8.6:1;
median age, 42 years; range, 21-80 years) had treatment for chronic disabling obstructive venous insufficiency with
iliocaval stenosis or occlusion. The clinical class of CEAP was 2 in 11 limbs, 3 in 31, 4 in 4, 5 in 1, and 6 in 1; etiology
was primary in 32 patients, secondary in 10, and congenital in 2. Anatomic involvement included superficial veins in 16
patients and perforator veins in 11. Obstruction was associated with superficial reflux in 4 patients, deep reflux in 13, and
both in 13. Ten patients had occlusion. All procedures were performed in the operating roomwith perioperative angiography
and angioplasty with or without self-expanding stent implantation. Venous clinical severity and disability scores were
obtained before and after treatment. Patency and restenosis were evaluated by duplex Doppler ultrasonography.
Results: No perioperative death or pulmonary embolism occurred. The technical success rate was 95.5% (two recanaliza-
tion failures), and two (4.5%) perioperative stent migrations occurred. One early thrombosis (2.4%) was treated by
thrombectomy and creation of an arteriovenous fistula. One late death and one thrombosis occurred. Restenoses were
found in five patients and were all treated successfully (four needed iterative stenting). Median follow-up was 27 months
(range, 2-103 months). Median venous clinical severity score improved from 8.5 to 2, and median venous disability score
improved from 2 to 0. Cumulative primary, assisted primary, and secondary patency rates of the venous segments at 36
months were 73%, 88%, and 90%, respectively, in intention to treat. The survival rate was 100% at 12 months and 97.3%
at 60 months.
Conclusions: Endovascular treatment of benign iliocaval occlusive disease is a safe and efficient minimally invasive
technique with good mid-term patency rates. Moreover, it improves cases with obstruction only, as well as cases with
associated reflux and obstruction. Primary stenting should always be performed by using self-expanding stents deployed
under general anesthesia to avoid lumbar pain. In case of failure, the endovascular procedure does not preclude further
surgical reconstruction. (J Vasc Surg 2005;42:1138–44.)Iliocaval chronic occlusive lesions are very challenging
therapeutic conditions that influence the patient’s quality
of life and ability to work. Different surgical techniques
(mainly bypasses) have been used in the past.1-4 These
procedures are invasive and have given variable, but glo-
bally disappointing results, mainly for complex lesions, with
patency rates ranging from 54% to 88%.1-3 Balloon angio-
plasty and stents offer a new and very attractive approach to
such lesions. Although we have used endovascular tech-
niques since 1995,5,6 the goal of this study was to review
our results and to discuss the evolution of the initial tech-
nical choices according to our experience and the literature.
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1138MATERIALS AND METHODS
From November 1995 to June 2004, 44 consecutive
patients with chronic obstructive venous insufficiency were
admitted (intention to treat) for endovascular treatment of
symptomatic chronic nonmalignant iliocaval obstructive
lesions (stenoses or occlusions). The first nine cases were
already included in a previous article.5 All patients had
previously received appropriate medical treatment, includ-
ing compressive stockings, but remained disabled. Exclu-
sion criteria were factors that limited life expectancy to less
than 5 years, such as severe chronic obstructive pulmonary
disease, cardiac failure, and malignant disease.
There were 35 women and 9 men (female-male ratio,
3.9:1; median age, 42 years; range, 21-80 years). Previous
pregnancy was found in 28 patients. The thrombophilia
test performed in patients with a history of deep venous
thrombosis (DVT; n  18) or pulmonary embolism (n 
3) included protein C and S, antithrombin III, factor II and
V mutation, homocystinemia, and circulating anticoagu-
lant antibodies. It found two cases of factor V mutation,
one case of factor II mutation, and one case of factor XII
mutation. Moreover, one patient had autoimmune throm-
bopenia. Twelve patients had a history of varicose vein
surgery (10 long stripping of the greater saphenous vein,
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vein high ligation), 2 of urologic surgery for retroperitoneal
fibrosis, 3 of hysterectomy, and 2 of pelvic radiotherapy
(absence of residual tumoral mass).
The initial workup in all patients consisted of color
Doppler ultrasonography of the lower extremities and pel-
vis to identify obstructive lesions and detect superficial
and/or deep reflux and collateral pathways. We considered
that the lesion was significant when there was a greater than
50% stenosis associated with inflow obstruction: asymmet-
ric flow in the common femoral vein (CFV) and the pres-
ence of collateral pathways (the main one being the internal
iliac vein with reversed flow). Computed tomographic
venography (43 patients) or magnetic resonance venogra-
phy (1 patient) was performed for ascertainment of the
extent of the obstruction, visualization of the collateral
pathways, or differential diagnosis of May-Thurner syn-
drome. Preoperative iliocavography to assess the morphol-
ogy of the narrowing and visualize the collateral pathways
was performed in 15 patients, systematically in the early
days of our experience and later only in complex cases
(mainly before recanalization). In case of uncertainty re-
garding the presence or severity of venous stenosis, profile
iliocavography always made it possible to effectively assess
the size of the venous lumen.
Ten women had symptoms of pelvic congestion syn-
drome, including five previously treated by embolization,
and were re-explored for residual symptoms; only three of
them had symptomatic leg disease. Patients with pelvic
congestion syndrome only were classified C2. All the other
patients had disabling chronic obstructive venous insuffi-
ciency and had already been treated with elastic stockings.
The CEAP classification clinical scores7 were as follows:
C2 (varicose veins), 11 limbs (10 patients); C3 (edema), 31
limbs (28 patients); C4 (skin changes ascribed to venous
disease), 4 limbs; C5 (cicatrized ulceration with skin
changes), 1 limb; and C6 (active ulceration), 1 limb. These
symptoms were usually unilateral for patients with left
iliocaval stenosis, but three had bilateral lower extremity
pain that increased in the evening and decreased in the
decubitus position. Four other patients had bilateral symp-
toms associated with bilateral iliac veins and inferior vena
cava (IVC) obstructive lesions. All patients with C4 to C6
lesions had a history of DVT except for one, who had
retroperitoneal fibrosis. Only two patients classified as C2
had a history of DVT (one ipsilateral leg DVT and one left
ovarian vein DVT).
The etiology was primary (May-Thurner syndrome) in
32 patients (73%), secondary in 10 (23%; postthrombotic
disease in 8 and retroperitoneal fibrosis in 2), and congen-
ital (hypoplasia) in 2 (4%). The anatomic repartition of the
diseased venous segment was deep veins in all patients, but
superficial and perforator vein lesions were present in 16
and in 11 patients, respectively.
The pathophysiology was obstruction in all patients.
Moreover, duplex scan showed that 30 patients had an
associated reflux: superficial reflux only in 4 patients, deep
reflux only in 13 patients, and both in 13 patients. Allpatients with pelvic congestion syndrome had a reflux in the
left internal iliac vein. In case of skin damage (6 patients),
deep reflux to below the knee was always found. CEAP
classification stratification is shown in Table I.
In all cases but one, there were occlusive lesions on the
left side. Bilateral iliac and IVC lesions were found in four
patients (9%). The left-right lower limb ratio was 8.6:1.
Complete occlusion was present in 10 patients (23%) with
a mean length of 133 mm. Extensive lesions (more than 1
venous segment) were found 11 times (25%). The homo-
lateral CFV and external iliac veins (EIVs) were involved six
times (14%).
All procedures were performed in the operating room
under general (n  24) or local (n  20) anesthesia.
Percutaneous access was performed through the CFV(s) in
all patients but five, who had the surgical approach of the
CFV (two with a history of DVT involving the CFV and
three who had simultaneous greater saphenous vein high
resection). After catheterization of the lesion and face with
or without profile iliocavography, nadroparin 30 mg/kg,
500 mg of aspirin, and cefamandole for infection prophy-
laxis were given intravenously. Balloon angioplasty was
performed before deployment of self-expanding metallic
stents (Wallstent, Boston Scientific-Schneider, Minneapo-
lis, Minn). Completion angiography was performed, and
sheaths were retrieved before direct smooth compression.
Elastic stockings were put on, and patients were taken to
bed until day 1. The postoperative treatment was initially
fluindione for 6 months; since 2003, patients have been
discharged on nadroparin for 15 days, and antiplatelet
drugs (unless there are other indications for fluindione) are
present.
Follow-up was scheduled at 1, 3, 6, and 12 months and
then annually. It included clinical examination and duplex
scanning. Venous clinical severity (VCSS) and venous dis-
ability (VDS) scores8 were evaluated before surgery and
Table I. CEAP classification of 48 limbs (bilateral lesions
treated in 4 patients)
Category No. patients
Clinical grade (all symptomatic)
2 10 (11 limbs)






Secondary 10 (12 limbs)
Congenital 2 (4 limbs)
Anatomy




Obstruction only 14 (18 limbs)
Reflux/obstruction 30during the follow-up to assess clinical results. In case of
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Doppler ultrasonography (50% of in-stent restenosis with
inflow obstruction was considered significant), transfemo-
ral venography was performed. Primary, assisted primary,
and secondary patency rates were calculated by using sur-
vival analysis with the life-table method.
RESULTS
No perioperative death or pulmonary embolism oc-
curred. All stenoses were successfully treated (Fig 1). Eight
recanalizations were performed with success (Fig 2), and
two failed (bilateral common iliac vein [CIV] and IVC
agenesis and one left femoroiliac chronic thrombosis). All
in all, 57 venous segments were treated: 4 IVCs, 42 CIVs,
6 EIVs, and 5 CFVs. The technical success rate was 95.5%
but was only 80% for recanalizations.
Three patients (7.3%) had angioplasty only because left
CIV stenoses were found to be moderate at iliocavography
during the procedure (50% stenosis), whereas the preoper-
ative duplex scan and computed tomographic scan revealed
Fig 1. Perioperative angiography in a patient with pelv
A, Computed tomographic scan showing left common
common iliac vein with large transversal collateral pathw
are no longer opacified.
Fig 2. A 32-year-old woman who had had left deep venous
thrombosis during pregnancy 2 years before. A, Angiography
showing complete occlusion of the left common iliac vein with
large transversal and ascendant collateral pathways. B, After recan-
alization and stenting with an 80-mm-long Wallstent.50% left CIV compression.Fifty-eight stents (12-16 mm in diameter and 40-90
mm long) were used: 2 in the IVC, 45 in the CIV, 6 in the
EIV, and 3 in the CFV. In one case, a kissing stent was
performed in the iliocaval junction, and two CFVs were
dilated but not stented. Moreover, six left CIVs were
treated with two stents. The mean number of stents for
treating the lesions per patient was 1.37.1-4 The mean
length of stented vein was 73 mm (range, 40-220 mm). In
two patients, a stent migrated during the procedure. One
stent jumped into the retrohepatic IVC: it was pulled down
into the infrarenal IVC, where it adopted a transversal
position; another stent was deployed in the iliocaval junc-
tion. The patient was asymptomatic 33 months later, and
the stent did not migrate. Another stent was pulled back
from the right atrium down to the left CFV with two
Amplatz Goose Neck Snare kits (ev3, Inc, Plymouth,
Minn), where it was retrieved surgically. Another stent was
accurately deployed 3 months later.
Concomitant procedures were performed in five pa-
tients: two left greater saphenous vein high resections (one
iterative), one left greater saphenous vein stripping, one left
lesser saphenous vein high resection, and one skin grafting
(the patient had an active ulcer). One patient had throm-
bosis 6 days after EIV recanalization; surgical thrombec-
tomy with balloon angioplasty of the stent and creation of
an arteriovenous fistula were performed with good results.
He was discharged at day 14. Another patient had postop-
erative bleeding through the puncture hole which was
stopped after redoing the compressive bandage.
All the other patients had a postoperative period with-
out complication. One patient stayed 13 days because he
had secondary left calf endoscopic perforant vein ligature
and left saphenous vein stripping at day 11, and one patient
stayed 10 days for skin grafting. The median hospital stay
was 3 days (range, 1-14 days). Thirty-two patients were
discharged with fluindione (8 patients since 2003 due to
history of DVT, which was associated with pulmonary
embolism in 2 and hypercoagulability in 3), and 12 were
ngestion syndrome caused by May-Thurner syndrome.
vein stenosis. B, Angiography: tight stenosis of the left
, After angioplasty and stenting, the collateral pathwaysic co
iliac
ays. Cdischarged with nadroparin and antiplatelet drugs.
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months). One patient died from carcinomatosis 16 months
later with a patent stent.
In case of skin damage, improvement occurred in all
Fig 3. Restenosis at 8 months. A, Color Doppler scan s
Face and profile angiography showing restenosis due to
collateral pathways. D and E, Face and profile angiogra
regression of the collateral pathways.patients but one, who underwent angioplasty alone. Theulcerated limb healed and stayed healed until the last follow-
up at 38 months. Duplex scan showed that reflux was not
modified in four and was improved in two.
One late thrombosis (2.4%) occurred at 15 months,
g an angulation at the caudal side of the stent. B and C,
gulation of the vein at the caudal side of the stent with
after iterative stenting: absence of residual stenosis andhowin
an an
phyand a Palma procedure was performed, with good results.
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a 9 months’ (range, 4-27 months) symptom-free period
and was detected by means of the duplex scan. One patient
who initially had CFV and EIV recanalization for postra-
Fig 4. Cumulative primary, assisted primary, and secon
treatment of chronic iliocaval occlusive disease (intention
primary patency, at 48 months for assisted primary pate
represented as dotted lines when SEM is 10%).
Table II. Results of the published series of endovascular t
varying etiology
Variable n Technical success 
O’Sullivan9 20 
Nazarian10 56 92% 
Blättler11 14 85.7% 
45
Neglen12 5 
Hurst13 18 100% 
Hartung 44 95.5%
PP, primary patency rate; SP, secondary patency rate.diotherapy thrombosis had angioplasty only at 13 monthsto treat a symptomatic 80% in-stent restenosis, with a good
initial result, but iterative restenosis nevertheless occurred
at 16 months, and a Palma procedure was performed. The
four other patients had restenosis (symptomatic in three) of
patency rates of 44 patients admitted for endovascular
at). Standard error was more than 10% at 30 months for
nd at 57 months for secondary patency (the curves are
ent for chronic iliocaval occlusive disease of
at 12 mo Late PP Late SP
3.9%
0% 50% at 48 mo 75% at 48 mo
9%
75% at 36 mo 93% at 36 mo
9%








8the iliac vein at the caudal side of stents implanted in the
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angioplasty and stenting (Fig 3).
Of the three patients who had isolated angioplasty, one
improved slightly, and one had no improvement. For the
third, the symptoms initially disappeared but recurred at 16
months, and a duplex scan showed left CIV restenosis. The
median VCSS and VDS were, respectively, 8.5 (range,
4-18) and 2 (range, 2-3) before surgery and 2 (range 0-9)
and 0 (range 0-2) at the end of the follow-up.
Table II and Fig 4 show the patency rates. Primary
patency, assisted primary patency, and secondary patency
rates were 73.2%, 87.6%, and 89.9%, respectively, at 36 and
60 months. The survival rate was 97.3% at 60 months.
DISCUSSION
Chronic venous occlusive disease, though generally not
life threatening, is a severe and disabling pathology that
occurs mainly in young patients and restricts their ability to
work. Medical treatment, mainly represented by compres-
sive therapy, is applied, but improvement is not always
enough to make a normal lifestyle possible. Several teams
have reported on studies of angioplasty with or without
stenting,9-13 with good results (Table II). Thus, stenting is
the method of choice to treat iliocaval obstructive disease.
In our experience, treatment of isolated May-Thurner
syndrome was performed with use of local anesthesia in 20
patients. Although this technique has several advantages for
the patient, it is not comfortable as a result of very intense
acute and durable back pain from stent implantation.
Moreover, treatment of complications (ie, stent migration)
with the patient under local anesthesia can be very difficult,
whereas general anesthesia offers the possibility of using
other approaches. That is why we currently perform such
procedures with patients under general anesthesia.
Angioplasty only was used three times onMay-Thurner
syndrome cases because the stenoses did not look signifi-
cant. Moreover, one patient was only 22 years old and had
only bilateral edema. This last patient was the only one of
the three whose condition really improved, but the symp-
toms reappeared 16 months later with restenosis at the
duplex scan. On the basis of this, it can be said that stenting
should always be performed.
The choices of stent configuration, length, diameter, and
position, aswell as postoperative treatment, arewithout doubt
important, particularly in the treatment of left CIV lesions.
Self-expanding metallic stents have already been used on
venous lesions, with good results.14 We used a balloon-ex-
pandable stent only in two cases reported previously.5 In one
case, the stent was implanted in a pregnant woman after left
femoroiliac venous thrombectomy. Despite excellent imme-
diate results, iterative thrombosis occurred 2 months later,
and the stent was completely crushed.
Initially, we used 14-mm-diameter and 30-mm-long
stents. Experience has shown that this choice was not the
right one. First, two stents jumped because of vein elastic
recoil. Moreover, proximal or distal restenoses occurred
despite initially excellent-looking results and were believedto be due to underestimated lesion length. This is certainly
due to the poor accuracy of angiography, even when face
and profile were used to evaluate the extent of the lesions.
Intravascular ultrasonography is the best way to estimate
them,15 but this device is not available in our institution.
We were also reluctant to put the distal end of the stent
across the iliocaval confluence. Neglen and Raju16 showed
that such a placement was needed and did not induce right
iliac vein thrombosis. In our experience, this condition
occurred in one case after stenting in a patient with auto-
immune thrombopenia despite efficient fluindion treat-
ment. For left CIV lesions, we commonly use stents that are
16 mm in diameter and at least 60 mm long, with the distal
end largely protruding into the IVC.
At the beginning of our experience, all patients who
had iliocaval stenting were discharged on fluindione for 6
months. Today, only patients treated for acute DVT or
post-DVT obstructive lesions and those who have had
recanalization receive such treatment. Patients with coagu-
lation anomalies or other reasons for fluindion will also
have this treatment. All others are treated with nadroparin
for 15 days and aspirin or clopidogrel for 6 to 12 months.
Despite Raju and colleagues’ good results with aspirin only,14
we are reluctant to adopt this because of the lack of refer-
ences on the role of antiplatelet drugs in venous disease.
The improvement of VCSS and VDS confirmed that
stenting is an effective way to treat occlusive lesions, as
Neglen et al17 stated. Initial clinical presentation found
severe venous disease (C4 to C6) only in patients who had
the association of obstruction and reflux. All but one had a
history of DVT. All these patients had clinical improvement
after stenting, and reflux was improved in two cases only
but never worsened.
Taking all patients with stents into consideration, throm-
bosis occurred in two patients (one acute and one late; 5.1%),
and restenosis occurred in five patients (12.8%). These results
are in line with those of Neglen and Raju,16 who reported a
thrombosis rate of 4% and a50% restenosis rate of 17% at 3
years. In one case, angioplasty only was performed because
of in-stent restenosis on a stent implanted for left CFV and
EIV recanalization. When restenosis occurred on iliac veins
at the end of the stent(s) (four cases), it was always treated
successfully by iterative angioplasty and stenting.
CONCLUSION
Angioplasty and stenting is a safe and efficient mini-
mally invasive technique for treatment of iliocaval occlusive
disease. Mid-term patency rates are good, and this tech-
nique does not preclude subsequent open operation in case
of failure.
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This is an important, well-written report from an active venous
center with early experience of percutaneous stenting of the il-
iofemoral venous outflow tract. The study shows a high technical
success rate of stent placement: thrombotic occlusion in 5%; cu-
mulative primary and secondary patency rates of 73% and 90%,
respectively, at 36 months; an in-stent restenosis (50%) rate of
13%; and a substantial clinical improvement of the patients. These
numbers are amazingly close to our group’s experience.
The article confirms that endovenous stenting is presently the
method of choice in the treatment of iliocaval outflow obstruction.
Even occlusion canmore often than not be successfully recanalized
and stented. Improved outflow ameliorates the patient’s symptoms
regardless of associated reflux, and, if present, the reflux does not
deteriorate after stent placement. Venous stenting may be consid-
ered a primary intervention in all limbs with chronic disease,
including iliocaval obstruction. In the presence of great saphenous
vein reflux, we have successfully combined the stenting with per-
cutaneous great saphenous vein ablation with or withoutminiphle-
bectomies, thus maintaining the minimally invasive nature of the
procedure.
It is interesting to note that the problems the authors encoun-endovenous stenting procedure; they resulted in technical modifi-
cations. The procedure is better performed with the patient under
full anesthesia, because the recanalization procedure can be time
consuming and the angioplasty is usually painful. Angioplasty
alone is insufficient, and all obstructions should be stented. It is
important to cover the entire lesion with the stent. Oblique veno-
graphic projections were used in this study to identify the extent of
the stenosis, but even multiplane venographies are inferior to
intravascular ultrasonography, which, in my opinion, is vital for
appropriate stent placement. Complete stenting of the lesion pre-
vents early occlusion of the stent and distal restenosis or angling. It
is only with too short a braided stent, which is inadequate to cover
the stenosis, that proximal migration occurs. It is safer and of no
disadvantage to overstent rather than understent a lesion.
On the basis of duplex Doppler findings, this study considered
greater than 50% stenosis with collateral formation significant. This
is an arbitrarily chosen number based on morphologic investiga-
tions, as in other studies. In fact, it is not known at what degree a
venous stenosis is hemodynamically significant, and, thus, no
reliable hemodynamic test exists. Not until such a test has been
found can borderline obstruction be diagnosed accurately and
patients correctly selected for stenting.
